Thomas Cannell, Sesen Bio CEO
February 14, 2023 11:16 AM ESTUpdated 05:56 PM
Financing
Deals

Sesen Bio reach­es deal with in­vestor group, paving way for Caris­ma merg­er

Paul Schloesser

Associate Editor

With a new deal, Sesen Bio’s merg­er with CAR-M play­er Caris­ma Ther­a­peu­tics is fi­nal­ly get­ting the sig­nal to move for­ward.

The deal,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times